Elotuzumab Biosimilar – Anti-SLAMF7, CD319 mAb – Research Grade

Description of Elotuzumab Biosimilar - Anti-SLAMF7, CD319 mAb - Research Grade

Elotuzumab Biosimilar – Anti-SLAMF7, CD319 mAb – Research Grade

Elotuzumab Biosimilar – Anti-SLAMF7, CD319 mAb – Research Grade: A Promising Antibody for Targeting SLAMF7 in

Cancer Treatment Introduction

Elotuzumab Biosimilar is a monoclonal antibody (mAb) that specifically targets SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7), also known as CD319. It is a research grade biosimilar of the FDA-approved therapeutic antibody, Elotuzumab, used for the treatment of multiple myeloma. In this article, we will discuss the structure, mechanism of action, and potential applications of Elotuzumab Biosimilar in cancer treatment.

Structure of Elotuzumab Biosimilar

Elotuzumab Biosimilar is a humanized IgG1 kappa monoclonal antibody with a molecular weight of approximately 148 kDa. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of the antibody is responsible for its specificity towards SLAMF7, while the constant region determines its effector functions.

The antibody structure is stabilized by disulfide bonds and glycosylation, which also contribute to its stability and half-life in the body. Elotuzumab Biosimilar has a similar structure to Elotuzumab, with minor differences in the amino acid sequence, making it a highly similar and potentially interchangeable alternative for clinical use.

Mechanism of Action

SLAMF7 is a cell surface receptor that is highly expressed on the surface of multiple myeloma cells and natural killer (NK) cells. It plays a crucial role in cell signaling and immune response regulation. Elotuzumab Biosimilar binds to SLAMF7 on the surface of cancer cells, leading to the activation of NK cells and the induction of antibody-dependent cellular cytotoxicity (ADCC).

In addition, Elotuzumab Biosimilar also has the ability to directly induce apoptosis in cancer cells by activating the caspase pathway. This dual mechanism of action makes Elotuzumab Biosimilar a potent and effective therapeutic agent for the treatment of multiple myeloma and other SLAMF7-expressing cancers.

Potential Applications

Elotuzumab Biosimilar has shown promising results in preclinical studies and is currently undergoing clinical trials for the treatment of multiple myeloma and other SLAMF7-expressing cancers, such as lymphoma and chronic lymphocytic leukemia.

As a research grade biosimilar, Elotuzumab Biosimilar can also be used in laboratory research to study the role of SLAMF7 in cancer development and progression. It can also be used in combination with other therapeutic agents, such as chemotherapy and immunotherapy, to enhance their efficacy and improve patient outcomes.

Conclusion

Elotuzumab Biosimilar is a highly specific and potent antibody that targets SLAMF7, a key receptor involved in cancer development and immune response regulation. Its unique mechanism of action and structural similarity to the FDA-approved Elotuzumab make it a promising therapeutic option for the treatment of multiple myeloma and other SLAMF7-expressing cancers. Further research and clinical trials will help establish its efficacy and safety in cancer treatment.

Keywords:

Elotuzumab Biosimilar, SLAMF7, CD319, monoclonal antibody, cancer treatment, therapeutic target, research grade, antibody-dependent cellular cytotoxicity, apoptosis, preclinical studies, clinical trials, immunotherapy, chemotherapy.

SDS-PAGE for Elotuzumab Biosimilar - Anti-SLAMF7, CD319 mAb

Elotuzumab Biosimilar - Anti-SLAMF7, CD319 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.